BrainsWay Ltd. (BWAY)

IL — Healthcare Sector
Peers: ICCM  BRSYF  SRDX  SSKN  ARDS  AFIB  STIM  APYX 

Automate Your Wheel Strategy on BWAY

With Tiblio's Option Bot, you can configure your own wheel strategy including BWAY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BWAY
  • Rev/Share 2.3554
  • Book/Share 3.4553
  • PB 3.8694
  • Debt/Equity 0.0873
  • CurrentRatio 5.0253
  • ROIC 0.0196

 

  • MktCap 252624145.0
  • FreeCF/Share 0.4345
  • PFCF 31.5111
  • PE 62.9759
  • Debt/Assets 0.0555
  • DivYield 0
  • ROE 0.0735

 

  • Rating B-
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 1
  • P/B Score 3
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Is the Options Market Predicting a Spike in Brainsway Stock?
BWAY
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Neutral

Investors need to pay close attention to Brainsway stock based on the movements in the options market lately.

Read More
image for news Is the Options Market Predicting a Spike in Brainsway Stock?
Wall Street Analysts Believe Brainsway (BWAY) Could Rally 30.98%: Here's is How to Trade
BWAY
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive

The mean of analysts' price targets for Brainsway (BWAY) points to a 31% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Read More
image for news Wall Street Analysts Believe Brainsway (BWAY) Could Rally 30.98%: Here's is How to Trade
Strength Seen in Brainsway (BWAY): Can Its 5.3% Jump Turn into More Strength?
BWAY
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive

Brainsway (BWAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Read More
image for news Strength Seen in Brainsway (BWAY): Can Its 5.3% Jump Turn into More Strength?
Are Medical Stocks Lagging Brainsway (BWAY) This Year?
BWAY
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Negative

Here is how Brainsway Ltd. Sponsored ADR (BWAY) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Read More
image for news Are Medical Stocks Lagging Brainsway (BWAY) This Year?
Brainsway Ltd. Sponsored ADR (BWAY) Hits Fresh High: Is There Still Room to Run?
BWAY
Published: June 12, 2025 by: Zacks Investment Research
Sentiment: Positive

Brainsway (BWAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Read More
image for news Brainsway Ltd. Sponsored ADR (BWAY) Hits Fresh High: Is There Still Room to Run?
Brainsway (BWAY) is on the Move, Here's Why the Trend Could be Sustainable
BWAY
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive

Brainsway (BWAY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Read More
image for news Brainsway (BWAY) is on the Move, Here's Why the Trend Could be Sustainable
Does Brainsway (BWAY) Have the Potential to Rally 43.88% as Wall Street Analysts Expect?
BWAY
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive

The mean of analysts' price targets for Brainsway (BWAY) points to a 43.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Read More
image for news Does Brainsway (BWAY) Have the Potential to Rally 43.88% as Wall Street Analysts Expect?
Earnings Estimates Moving Higher for Brainsway (BWAY): Time to Buy?
BWAY
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive

Brainsway (BWAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Read More
image for news Earnings Estimates Moving Higher for Brainsway (BWAY): Time to Buy?
Wall Street Analysts See a 41.31% Upside in Brainsway (BWAY): Can the Stock Really Move This High?
BWAY
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Positive

The average of price targets set by Wall Street analysts indicates a potential upside of 41.3% in Brainsway (BWAY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Read More
image for news Wall Street Analysts See a 41.31% Upside in Brainsway (BWAY): Can the Stock Really Move This High?
BrainsWay Ltd. (BWAY) Q1 2025 Earnings Call Transcript
BWAY
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Neutral

BrainsWay Ltd. (NASDAQ:BWAY ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Brian Ritchie – LifeSci Advisors LLC Hadar Levy – Chief Executive Officer Ido Marom – Chief Financial Officer Conference Call Participants Steve Lichtman – Oppenheimer & Company Operator Good day, and welcome to the BrainsWay First Quarter 2025 Earnings Conference Call.

Read More
image for news BrainsWay Ltd. (BWAY) Q1 2025 Earnings Call Transcript
BrainsWay Ltd. (BWAY) Q4 2024 Earnings Call Transcript
BWAY
Published: March 11, 2025 by: Seeking Alpha
Sentiment: Neutral

BrainsWay Ltd. (NASDAQ:BWAY ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Hadar Levy - Chief Executive Officer Ido Marom - Chief Financial Officer Conference Call Participants Steven Lichtman - Oppenheimer Jeffrey S.

Read More
image for news BrainsWay Ltd. (BWAY) Q4 2024 Earnings Call Transcript
BWAY Drops 15% in Four Days: How to Play the Stock Before Earnings?
BWAY
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Negative

BrainsWay BWAY shares plunged 15.7% in the past four trading sessions, falling below the 50-day moving average, implying weakness in the stock. Meanwhile, BWAY is scheduled to release its fourth-quarter results on March 11.

Read More
image for news BWAY Drops 15% in Four Days: How to Play the Stock Before Earnings?
Brainsway (BWAY) Is a Great Choice for 'Trend' Investors, Here's Why
BWAY
Published: February 21, 2025 by: Zacks Investment Research
Sentiment: Positive

If you are looking for stocks that are well positioned to maintain their recent uptrend, Brainsway (BWAY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Read More
image for news Brainsway (BWAY) Is a Great Choice for 'Trend' Investors, Here's Why
5 Stocks With Recent Price Strength to Enhance Your Portfolio
BWAY, BYRN, FCCO, SBFG, SNEX
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are SBFG, FCCO, SNEX, BYRN, BWAY.

Read More
image for news 5 Stocks With Recent Price Strength to Enhance Your Portfolio

About BrainsWay Ltd. (BWAY)

  • IPO Date 2019-04-17
  • Website https://www.brainsway.com
  • Industry Medical - Devices
  • CEO Hadar Levy
  • Employees 120

Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.